4-Phenylbutyric Acid
The therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Hydrocortisone.
Acarbose
The therapeutic efficacy of Acarbose can be decreased when used in combination with Hydrocortisone.
Aceclofenac
The risk or severity of adverse effects can be increased when Aceclofenac is combined with Hydrocortisone.
Advertisement
Acemetacin
The risk or severity of adverse effects can be increased when Acemetacin is combined with Hydrocortisone.
Acetohexamide
The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Hydrocortisone.
Acetyl salicylate
The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Hydrocortisone.
Advertisement
Adapalene
The risk or severity of adverse effects can be increased when Adapalene is combined with Hydrocortisone.
Afatinib
The serum concentration of Afatinib can be increased when it is combined with Hydrocortisone.
Aldesleukin
Hydrocortisone may decrease the antineoplastic activities of Aldesleukin.
Advertisement
Alminoprofen
The risk or severity of adverse effects can be increased when Alminoprofen is combined with Hydrocortisone.
Alogliptin
The therapeutic efficacy of Alogliptin can be decreased when used in combination with Hydrocortisone.
Aloxiprin
The risk or severity of adverse effects can be increased when Aloxiprin is combined with Hydrocortisone.
Aluminum
The bioavailability of Hydrocortisone can be decreased when combined with Aluminium.
Aluminum Hydroxide
The bioavailability of Hydrocortisone can be decreased when combined with Aluminum hydroxide.
aluminum hydroxide, dried (USP)
The bioavailability of Hydrocortisone can be decreased when combined with Aluminum hydroxide.
Aluminum Magnesium Silicate
The bioavailability of Hydrocortisone can be decreased when combined with Almasilate.
Ambenonium
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Ambenonium.
Aminosalicylic Acid
The risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Hydrocortisone.
Amiodarone
The metabolism of Hydrocortisone can be decreased when combined with Amiodarone.
Amphotericin B
Hydrocortisone may increase the hypokalemic activities of Amphotericin B.
amphotericin B liposomal
Hydrocortisone may increase the hypokalemic activities of Amphotericin B.
Anhydrous Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Hydrocortisone.
Anthrax immune globulin, human
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Anthrax immune globulin human.
Antipyrine
The risk or severity of adverse effects can be increased when Antipyrine is combined with Hydrocortisone.
Apalutamide
The serum concentration of Hydrocortisone can be decreased when it is combined with Apalutamide.
Apazone
The risk or severity of adverse effects can be increased when Azapropazone is combined with Hydrocortisone.
Apremilast
The risk or severity of adverse effects can be increased when Apremilast is combined with Hydrocortisone.
Aprepitant
The serum concentration of Hydrocortisone can be increased when it is combined with Aprepitant.
Aripiprazole
The serum concentration of Aripiprazole can be decreased when it is combined with Hydrocortisone.
Aspirin
The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Hydrocortisone.
Atazanavir
The metabolism of Hydrocortisone can be decreased when combined with Atazanavir.
Atomoxetine
The metabolism of Hydrocortisone can be decreased when combined with Atomoxetine.
Atorvastatin
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Atorvastatin.
Atracurium Besylate
Atracurium besylate may increase the adverse neuromuscular activities of Hydrocortisone.
Azelastine
The risk or severity of adverse effects can be increased when Azelastine is combined with Hydrocortisone.
Azosemide
Hydrocortisone may increase the hypokalemic activities of Azosemide.
Balsalazide
The risk or severity of adverse effects can be increased when Balsalazide is combined with Hydrocortisone.
BCG Vaccine
The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Hydrocortisone.
BCG, Live, Connaught Strain
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Bacillus calmette-guerin substrain connaught live antigen.
BCG, Live, Tice Strain
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Bacillus calmette-guerin substrain tice live antigen.
Bendroflumethiazide
Hydrocortisone may increase the hypokalemic activities of Bendroflumethiazide.
Benzoic Acid
The therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Hydrocortisone.
Benzydamine
The risk or severity of adverse effects can be increased when Benzydamine is combined with Hydrocortisone.
Bismuth Subcitrate
The bioavailability of Hydrocortisone can be decreased when combined with Bismuth Subcitrate.
Boceprevir
The metabolism of Hydrocortisone can be decreased when combined with Boceprevir.
Bortezomib
The metabolism of Hydrocortisone can be decreased when combined with Bortezomib.
Bosentan
The serum concentration of Hydrocortisone can be decreased when it is combined with Bosentan.
Bosutinib
The serum concentration of Bosutinib can be increased when it is combined with Hydrocortisone.
Bosutinib monohydrate
The serum concentration of Bosutinib can be increased when it is combined with Hydrocortisone.
Brentuximab Vedotin
The serum concentration of Brentuximab vedotin can be increased when it is combined with Hydrocortisone.
Bromfenac
The risk or severity of adverse effects can be increased when Bromfenac is combined with Hydrocortisone.
Bromocriptine
The risk or severity of adverse effects can be increased when Bromocriptine is combined with Hydrocortisone.
Bufexamac
The risk or severity of adverse effects can be increased when Bufexamac is combined with Hydrocortisone.
Bumetanide
Hydrocortisone may increase the hypokalemic activities of Bumetanide.
Cabergoline
The risk or severity of adverse effects can be increased when Cabergoline is combined with Hydrocortisone.
Calcitriol
The therapeutic efficacy of Calcitriol can be decreased when used in combination with Hydrocortisone.
Calcium Carbonate
The bioavailability of Hydrocortisone can be decreased when combined with Calcium Carbonate.
CALCIUM CARBONATE, PRECIPITATED
The bioavailability of Hydrocortisone can be decreased when combined with Calcium Carbonate.
Canagliflozin
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Hydrocortisone.
Canagliflozin Anhydrous
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Hydrocortisone.
Capromab Pendetide
Hydrocortisone may decrease effectiveness of Capromab pendetide as a diagnostic agent.
Carbamazepine
The serum concentration of Hydrocortisone can be decreased when it is combined with Carbamazepine.
Carprofen
The risk or severity of adverse effects can be increased when Carprofen is combined with Hydrocortisone.
Celecoxib
The risk or severity of adverse effects can be increased when Celecoxib is combined with Hydrocortisone.
Ceritinib
The serum concentration of Hydrocortisone can be increased when it is combined with Ceritinib.
Cerivastatin
The serum concentration of Cerivastatin can be increased when it is combined with Hydrocortisone.
Chloroquine
The risk or severity of adverse effects can be increased when Chloroquine is combined with Hydrocortisone.
Chlorothiazide
Hydrocortisone may increase the hypokalemic activities of Chlorothiazide.
Chlorotrianisene
The serum concentration of Hydrocortisone can be increased when it is combined with Chlorotrianisene.
Chlorpropamide
The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Hydrocortisone.
Chlorthalidone
Hydrocortisone may increase the hypokalemic activities of Chlorthalidone.
Cholestyramine Resin
Cholestyramine can cause a decrease in the absorption of Hydrocortisone resulting in a reduced serum concentration and potentially a decrease in efficacy.
Choline Magnesium Trisalicyclate
The risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Hydrocortisone.
Cinoxacin
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Cinoxacin.
Clarithromycin
The metabolism of Hydrocortisone can be decreased when combined with Clarithromycin.
Clemastine
The metabolism of Hydrocortisone can be decreased when combined with Clemastine.
Clonixin
The risk or severity of adverse effects can be increased when Clonixin is combined with Hydrocortisone.
Clotrimazole
The metabolism of Hydrocortisone can be decreased when combined with Clotrimazole.
Cobicistat
The metabolism of Hydrocortisone can be decreased when combined with Cobicistat.
Colchicine
The serum concentration of Colchicine can be increased when it is combined with Hydrocortisone.
Colesevelam
Colesevelam can cause a decrease in the absorption of Hydrocortisone resulting in a reduced serum concentration and potentially a decrease in efficacy.
Colestipol
Colestipol can cause a decrease in the absorption of Hydrocortisone resulting in a reduced serum concentration and potentially a decrease in efficacy.
Conivaptan
The serum concentration of Conivaptan can be increased when it is combined with Hydrocortisone.
Corticorelin Ovine
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Hydrocortisone.
Corticorelin Ovine Triflutate
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Hydrocortisone.
Crizotinib
The metabolism of Hydrocortisone can be decreased when combined with Crizotinib.
Curcumin
The risk or severity of adverse effects can be increased when Curcumin is combined with Hydrocortisone.
Cyclopenthiazide
Hydrocortisone may increase the hypokalemic activities of Cyclopenthiazide.
Cyclosporine
The metabolism of Hydrocortisone can be decreased when combined with Cyclosporine.
Dabigatran Etexilate
The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Hydrocortisone.
Dabrafenib
The serum concentration of Hydrocortisone can be decreased when it is combined with Dabrafenib.
Danazol
Hydrocortisone may increase the fluid retaining activities of Danazol.
Darunavir
The metabolism of Hydrocortisone can be decreased when combined with Darunavir.
Dasatinib
The serum concentration of Hydrocortisone can be increased when it is combined with Dasatinib.
Dasatinib Anhydrous
The serum concentration of Hydrocortisone can be increased when it is combined with Dasatinib.
Deferasirox
The serum concentration of Hydrocortisone can be decreased when it is combined with Deferasirox.
Delavirdine
The metabolism of Hydrocortisone can be decreased when combined with Delavirdine.
Demecarium
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Demecarium.
Denosumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Hydrocortisone.
Diclofenac
The risk or severity of adverse effects can be increased when Diclofenac is combined with Hydrocortisone.
Dienestrol
The serum concentration of Hydrocortisone can be increased when it is combined with Dienestrol.
Diethylstilbestrol
The serum concentration of Hydrocortisone can be increased when it is combined with Diethylstilbestrol.
Diflunisal
The risk or severity of adverse effects can be increased when Diflunisal is combined with Hydrocortisone.
Dihydroergotamine
The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Hydrocortisone.
Diltiazem
The metabolism of Hydrocortisone can be decreased when combined with Diltiazem.
Dipyrone
The risk or severity of adverse effects can be increased when Metamizole is combined with Hydrocortisone.
Distigmine
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Distigmine.
Donepezil
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Donepezil.
Doxorubicin
The serum concentration of Doxorubicin can be increased when it is combined with Hydrocortisone.
Doxorubicin Hydrochloride
The serum concentration of Doxorubicin can be increased when it is combined with Hydrocortisone.
Doxycycline
The metabolism of Hydrocortisone can be decreased when combined with Doxycycline.
Doxycycline Anhydrous
The metabolism of Hydrocortisone can be decreased when combined with Doxycycline.
Dronedarone
The metabolism of Hydrocortisone can be decreased when combined with Dronedarone.
Droxicam
The risk or severity of adverse effects can be increased when Droxicam is combined with Hydrocortisone.
Dulaglutide
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Hydrocortisone.
Echothiophate
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Echothiophate.
Edoxaban
The serum concentration of Edoxaban can be increased when it is combined with Hydrocortisone.
Edrophonium
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Edrophonium.
Empagliflozin
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Hydrocortisone.
Enoxacin
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Enoxacin.
Enzalutamide
The serum concentration of Hydrocortisone can be decreased when it is combined with Enzalutamide.
Equol, (-)-
The serum concentration of Hydrocortisone can be increased when it is combined with Equol.
Ergonovine
The risk or severity of adverse effects can be increased when Ergonovine is combined with Hydrocortisone.
Ergotamine
The risk or severity of adverse effects can be increased when Ergotamine is combined with Hydrocortisone.
Erythromycin
The metabolism of Hydrocortisone can be decreased when combined with Erythromycin.
Estradiol
The serum concentration of Hydrocortisone can be increased when it is combined with Estradiol.
Estradiol acetate
The serum concentration of Hydrocortisone can be increased when it is combined with Estradiol acetate.
Estradiol Cypionate
The serum concentration of Hydrocortisone can be increased when it is combined with Estradiol cypionate.
Estradiol Valerate
The serum concentration of Hydrocortisone can be increased when it is combined with Estradiol valerate.
Estriol
The serum concentration of Hydrocortisone can be increased when it is combined with Estriol.
Estrogens, Conjugated (USP)
The serum concentration of Hydrocortisone can be increased when it is combined with Conjugated estrogens.
Estrogens, Esterified (USP)
The serum concentration of Hydrocortisone can be increased when it is combined with Estrogens, esterified.
Estrone
The serum concentration of Hydrocortisone can be increased when it is combined with Estrone.
Etanercept
The risk or severity of adverse effects can be increased when Etanercept is combined with Hydrocortisone.
Ethacrynate
Hydrocortisone may increase the hypokalemic activities of Etacrynic acid.
Ethacrynic Acid
Hydrocortisone may increase the hypokalemic activities of Etacrynic acid.
Ethinyl Estradiol
The serum concentration of Hydrocortisone can be increased when it is combined with Ethinyl Estradiol.
Etodolac
The risk or severity of adverse effects can be increased when Etodolac is combined with Hydrocortisone.
Etofenamate
The risk or severity of adverse effects can be increased when Etofenamate is combined with Hydrocortisone.
Etoricoxib
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Hydrocortisone.
Evening primrose oil
The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Hydrocortisone.
Everolimus
The serum concentration of Everolimus can be increased when it is combined with Hydrocortisone.
Exenatide
The therapeutic efficacy of Exenatide can be decreased when used in combination with Hydrocortisone.
Felbinac
The risk or severity of adverse effects can be increased when Felbinac is combined with Hydrocortisone.
Fenbufen
The risk or severity of adverse effects can be increased when Fenbufen is combined with Hydrocortisone.
Fenoprofen
The risk or severity of adverse effects can be increased when Fenoprofen is combined with Hydrocortisone.
Ferulic Acid
The risk or severity of adverse effects can be increased when Ferulic acid is combined with Hydrocortisone.
Fingolimod
Hydrocortisone may increase the immunosuppressive activities of Fingolimod.
Fleroxacin
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Fleroxacin.
Floctafenine
The risk or severity of adverse effects can be increased when Floctafenine is combined with Hydrocortisone.
Fluconazole
The metabolism of Hydrocortisone can be decreased when combined with Fluconazole.
Flumequine
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Flumequine.
Fluoxymesterone
Hydrocortisone may increase the fluid retaining activities of Fluoxymesterone.
Flurbiprofen
The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Hydrocortisone.
Fluvastatin
The serum concentration of Fluvastatin can be increased when it is combined with Hydrocortisone.
Fluvoxamine
The metabolism of Hydrocortisone can be decreased when combined with Fluvoxamine.
Fosamprenavir
The metabolism of Hydrocortisone can be decreased when combined with Fosamprenavir.
Fosaprepitant
The serum concentration of Hydrocortisone can be increased when it is combined with Fosaprepitant.
Fosphenytoin
The serum concentration of Hydrocortisone can be decreased when it is combined with Fosphenytoin.
Furosemide
Hydrocortisone may increase the hypokalemic activities of Furosemide.
Fusidate
The serum concentration of Hydrocortisone can be increased when it is combined with Fusidic Acid.
Fusidic Acid
The serum concentration of Hydrocortisone can be increased when it is combined with Fusidic Acid.
Galantamine
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Galantamine.
Gallamine Triethiodide
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Gallamine Triethiodide.
Gatifloxacin
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Gatifloxacin.
Gatifloxacin Anhydrous
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Gatifloxacin.
Gemifloxacin
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Gemifloxacin.
Gemifloxacin Mesylate
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Gemifloxacin.
Genistein
The serum concentration of Hydrocortisone can be increased when it is combined with Genistein.
Ginkgo biloba extract
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Ginkgo biloba.
Glibornuride
The therapeutic efficacy of Glibornuride can be decreased when used in combination with Hydrocortisone.
Gliclazide
The therapeutic efficacy of Gliclazide can be decreased when used in combination with Hydrocortisone.
Glimepiride
The therapeutic efficacy of Glimepiride can be decreased when used in combination with Hydrocortisone.
Glipizide
The therapeutic efficacy of Glipizide can be decreased when used in combination with Hydrocortisone.
Gliquidone
The therapeutic efficacy of Gliquidone can be decreased when used in combination with Hydrocortisone.
Glyburide
The therapeutic efficacy of Glyburide can be decreased when used in combination with Hydrocortisone.
Glycerol Phenylbutyrate
The therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Hydrocortisone.
Grepafloxacin
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Grepafloxacin.
Hepatitis A Vaccine, Inactivated
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Hepatitis A Vaccine.
Hepatitis B Surface Antigen Vaccine
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Hepatitis B Vaccine (Recombinant).
Hyaluronidase
The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Hydrocortisone.
Hyaluronidase, Ovine
The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Hydrocortisone.
Hydrochlorothiazide
Hydrocortisone may increase the hypokalemic activities of Hydrochlorothiazide.
Hydroflumethiazide
Hydrocortisone may increase the hypokalemic activities of Hydroflumethiazide.
Hydrotalcite
The bioavailability of Hydrocortisone can be decreased when combined with Hydrotalcite.
Hypoxis hemerocallidea root extract
The serum concentration of Hydrocortisone can be decreased when it is combined with St. John's Wort.
Ibrutinib
The serum concentration of Ibrutinib can be increased when it is combined with Hydrocortisone.
Ibuprofen
The risk or severity of adverse effects can be increased when Ibuprofen is combined with Hydrocortisone.
Icatibant
The risk or severity of adverse effects can be increased when Icatibant is combined with Hydrocortisone.
Idelalisib
The metabolism of Hydrocortisone can be decreased when combined with Idelalisib.
Imatinib
The metabolism of Hydrocortisone can be decreased when combined with Imatinib.
Indacaterol
Indacaterol may increase the hypokalemic activities of Hydrocortisone.
Indapamide
Hydrocortisone may increase the hypokalemic activities of Indapamide.
Indinavir
The metabolism of Hydrocortisone can be decreased when combined with Indinavir.
INDINAVIR ANHYDROUS
The metabolism of Hydrocortisone can be decreased when combined with Indinavir.
Indobufen
The risk or severity of adverse effects can be increased when Indobufen is combined with Hydrocortisone.
Indomethacin
The risk or severity of adverse effects can be increased when Indomethacin is combined with Hydrocortisone.
Insulin Detemir
The therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Hydrocortisone.
Insulin Glargine
The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Hydrocortisone.
insulin human, rDNA origin
The therapeutic efficacy of Insulin Human can be decreased when used in combination with Hydrocortisone.
Insulin Lispro
The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Hydrocortisone.
Insulin, Aspart Protamine, Human
The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Hydrocortisone.
Insulin, Aspart, Human
The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Hydrocortisone.
Insulin, Glulisine, Human
The therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Hydrocortisone.
Insulin, Pork
The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Hydrocortisone.
Insulin, Protamine Lispro, Human
The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Hydrocortisone.
Insulin, Regular, Pork
The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Hydrocortisone.
Isavuconazole
The serum concentration of Hydrocortisone can be increased when it is combined with Isavuconazole.
Isavuconazonium
The metabolism of Hydrocortisone can be decreased when combined with Isavuconazonium.
Isoflurophate
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Isoflurophate.
Isoniazid
The serum concentration of Isoniazid can be decreased when it is combined with Hydrocortisone.
Isradipine
The metabolism of Hydrocortisone can be decreased when combined with Isradipine.
Itraconazole
The metabolism of Hydrocortisone can be decreased when combined with Itraconazole.
Ivacaftor
The serum concentration of Hydrocortisone can be increased when it is combined with Ivacaftor.
Kebuzone
The risk or severity of adverse effects can be increased when Kebuzone is combined with Hydrocortisone.
Ketoconazole
The metabolism of Hydrocortisone can be decreased when combined with Ketoconazole.
Ketoprofen
The risk or severity of adverse effects can be increased when Ketoprofen is combined with Hydrocortisone.
Ketorolac
The risk or severity of adverse effects can be increased when Ketorolac is combined with Hydrocortisone.
Lacidipine
The serum concentration of Lacidipine can be decreased when it is combined with Hydrocortisone.
Ledipasvir
The serum concentration of Ledipasvir can be increased when it is combined with Hydrocortisone.
Leflunomide
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Leflunomide.
Levofloxacin
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Levofloxacin.
Levofloxacin Anhydrous
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Levofloxacin.
Limonene, (+)-
The risk or severity of adverse effects can be increased when (4R)-limonene is combined with Hydrocortisone.
Linagliptin
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Hydrocortisone.
Liraglutide
The therapeutic efficacy of Liraglutide can be decreased when used in combination with Hydrocortisone.
Lisuride
The risk or severity of adverse effects can be increased when Lisuride is combined with Hydrocortisone.
Lopinavir
The metabolism of Hydrocortisone can be decreased when combined with Lopinavir.
Lornoxicam
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Hydrocortisone.
Lovastatin
The serum concentration of Lovastatin can be increased when it is combined with Hydrocortisone.
Loxoprofen
The risk or severity of adverse effects can be increased when Loxoprofen is combined with Hydrocortisone.
Luliconazole
The serum concentration of Hydrocortisone can be increased when it is combined with Luliconazole.
Lumacaftor
The serum concentration of Hydrocortisone can be decreased when it is combined with Lumacaftor.
Magaldrate
The bioavailability of Hydrocortisone can be decreased when combined with Magaldrate.
Magnesium Hydroxide
The bioavailability of Hydrocortisone can be decreased when combined with Magnesium hydroxide.
Magnesium Oxide
The bioavailability of Hydrocortisone can be decreased when combined with Magnesium oxide.
Magnesium Salicylate
The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Hydrocortisone.
Magnesium Trisilicate
The bioavailability of Hydrocortisone can be decreased when combined with Magnesium Trisilicate.
Malathion
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Malathion.
Masoprocol
The risk or severity of adverse effects can be increased when Masoprocol is combined with Hydrocortisone.
Meclofenamate
The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Hydrocortisone.
Meclofenamic Acid
The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Hydrocortisone.
Mefenamic Acid
The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Hydrocortisone.
Mefloquine
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Mefloquine.
Meloxicam
The risk or severity of adverse effects can be increased when Meloxicam is combined with Hydrocortisone.
Memantine
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Memantine.
Mesalamine
The risk or severity of adverse effects can be increased when Mesalazine is combined with Hydrocortisone.
Mesterolone
Hydrocortisone may increase the fluid retaining activities of Mesterolone.
Mestranol
The serum concentration of Hydrocortisone can be increased when it is combined with Mestranol.
Metergoline
The risk or severity of adverse effects can be increased when Metergoline is combined with Hydrocortisone.
Metformin
The therapeutic efficacy of Metformin can be decreased when used in combination with Hydrocortisone.
Methyclothiazide
Hydrocortisone may increase the hypokalemic activities of Methyclothiazide.
Methyl Salicylate
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Hydrocortisone.
Methylergonovine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Hydrocortisone.
Methyltestosterone
Hydrocortisone may increase the fluid retaining activities of Methyltestosterone.
Methysergide
The risk or severity of adverse effects can be increased when Methysergide is combined with Hydrocortisone.
Metoclopramide
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Metoclopramide.
Metolazone
Hydrocortisone may increase the hypokalemic activities of Metolazone.
Mifepristone
The therapeutic efficacy of Hydrocortisone can be decreased when used in combination with Mifepristone.
Miglitol
The therapeutic efficacy of Miglitol can be decreased when used in combination with Hydrocortisone.
Miglustat
The therapeutic efficacy of Miglustat can be decreased when used in combination with Hydrocortisone.
Minaprine
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Minaprine.
Mitotane
The serum concentration of Hydrocortisone can be decreased when it is combined with Mitotane.
Mivacurium
Mivacurium may increase the adverse neuromuscular activities of Hydrocortisone.
MYCOPHENOLATE
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Hydrocortisone.
Mycophenolate Mofetil
The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Hydrocortisone.
Mycophenolic Acid
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Hydrocortisone.
Nabumetone
The risk or severity of adverse effects can be increased when Nabumetone is combined with Hydrocortisone.
Naftifine
The risk or severity of adverse effects can be increased when Naftifine is combined with Hydrocortisone.
Nalidixic Acid
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Nalidixic Acid.
Naloxegol
The serum concentration of Naloxegol can be increased when it is combined with Hydrocortisone.
Nandrolone
Hydrocortisone may increase the fluid retaining activities of Nandrolone.
Nandrolone Decanoate
Hydrocortisone may increase the fluid retaining activities of Nandrolone decanoate.
Naproxen
The risk or severity of adverse effects can be increased when Naproxen is combined with Hydrocortisone.
Natalizumab
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Natalizumab.
Nateglinide
The therapeutic efficacy of Nateglinide can be decreased when used in combination with Hydrocortisone.
Nefazodone
The metabolism of Hydrocortisone can be decreased when combined with Nefazodone.
Nelfinavir
The metabolism of Hydrocortisone can be decreased when combined with Nelfinavir.
Neostigmine
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Neostigmine.
Nepafenac
The risk or severity of adverse effects can be increased when Nepafenac is combined with Hydrocortisone.
Netupitant
The serum concentration of Hydrocortisone can be increased when it is combined with Netupitant.
Nevirapine
The serum concentration of Hydrocortisone can be decreased when it is combined with Nevirapine.
Nicergoline
The risk or severity of adverse effects can be increased when Nicergoline is combined with Hydrocortisone.
Nicorandil
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Nicorandil.
Niflumic Acid
The risk or severity of adverse effects can be increased when Niflumic Acid is combined with Hydrocortisone.
Nilotinib
The metabolism of Hydrocortisone can be decreased when combined with Nilotinib.
Nimesulide
The risk or severity of adverse effects can be increased when Nimesulide is combined with Hydrocortisone.
Nintedanib
The serum concentration of Nintedanib can be increased when it is combined with Hydrocortisone.
Norfloxacin
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Norfloxacin.
O-PHENANTHROLINE
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with 1,10-Phenanthroline.
Ocrelizumab
Ocrelizumab may increase the immunosuppressive activities of Hydrocortisone.
Oenothera biennis seed extract
The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Hydrocortisone.
Olaparib
The metabolism of Hydrocortisone can be decreased when combined with Olaparib.
Olopatadine
The risk or severity of adverse effects can be increased when Olopatadine is combined with Hydrocortisone.
Olsalazine
The risk or severity of adverse effects can be increased when Olsalazine is combined with Hydrocortisone.
Osimertinib
The serum concentration of Hydrocortisone can be increased when it is combined with Osimertinib.
Oxandrolone
Hydrocortisone may increase the fluid retaining activities of Oxandrolone.
Oxaprozin
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Hydrocortisone.
Oxymetholone
Hydrocortisone may increase the fluid retaining activities of Oxymetholone.
Oxyphenbutazone
The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Hydrocortisone.
Palbociclib
The serum concentration of Hydrocortisone can be increased when it is combined with Palbociclib.
Parecoxib
The risk or severity of adverse effects can be increased when Parecoxib is combined with Hydrocortisone.
Parthenolide
The risk or severity of adverse effects can be increased when Parthenolide is combined with Hydrocortisone.
Pazopanib
The serum concentration of Pazopanib can be increased when it is combined with Hydrocortisone.
Pefloxacin
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Pefloxacin.
Pentobarbital
The serum concentration of Hydrocortisone can be decreased when it is combined with Pentobarbital.
Pergolide
The risk or severity of adverse effects can be increased when Pergolide is combined with Hydrocortisone.
Phenformin
The therapeutic efficacy of Phenformin can be decreased when used in combination with Hydrocortisone.
Phenobarbital
The serum concentration of Hydrocortisone can be decreased when it is combined with Phenobarbital.
Phenylacetic Acid
The therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Hydrocortisone.
Phenylbutazone
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Hydrocortisone.
Phenylbutyrate
The therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Hydrocortisone.
Phenytoin
The serum concentration of Hydrocortisone can be decreased when it is combined with Phenytoin.
Physostigmine
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Physostigmine.
Pimecrolimus
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Hydrocortisone.
Pioglitazone
The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Hydrocortisone.
Piretanide
Hydrocortisone may increase the hypokalemic activities of Piretanide.
Pirfenidone
The risk or severity of adverse effects can be increased when Pirfenidone is combined with Hydrocortisone.
Piroxicam
The risk or severity of adverse effects can be increased when Piroxicam is combined with Hydrocortisone.
Piroxicam-Beta-Cyclodextrin
The risk or severity of adverse effects can be increased when Piroxicam is combined with Hydrocortisone.
Pitavastatin
The serum concentration of Pitavastatin can be increased when it is combined with Hydrocortisone.
Polyestradiol Phosphate
The serum concentration of Hydrocortisone can be increased when it is combined with Polyestradiol phosphate.
Polythiazide
Hydrocortisone may increase the hypokalemic activities of Polythiazide.
Posaconazole
The metabolism of Hydrocortisone can be decreased when combined with Posaconazole.
Pramlintide
The therapeutic efficacy of Pramlintide can be decreased when used in combination with Hydrocortisone.
Pravastatin
The serum concentration of Pravastatin can be increased when it is combined with Hydrocortisone.
Primidone
The serum concentration of Hydrocortisone can be decreased when it is combined with Primidone.
Promestriene
The serum concentration of Hydrocortisone can be increased when it is combined with Promestriene.
Pyridostigmine
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Pyridostigmine.
Pyridostigmine Bromide
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Pyridostigmine.
Quinestrol
The serum concentration of Hydrocortisone can be increased when it is combined with Quinestrol.
Quinethazone
Hydrocortisone may increase the hypokalemic activities of Quinethazone.
Rabies Immune Globulin, Human
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Human rabies virus immune globulin.
Rabies Virus Vaccine Flury-Lep Strain
The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Hydrocortisone.
Ranolazine
The serum concentration of Ranolazine can be increased when it is combined with Hydrocortisone.
Rapacuronium
Rapacuronium may increase the adverse neuromuscular activities of Hydrocortisone.
Regular Insulin, Human
The therapeutic efficacy of Insulin Human can be decreased when used in combination with Hydrocortisone.
Repaglinide
The therapeutic efficacy of Repaglinide can be decreased when used in combination with Hydrocortisone.
Resveratrol
The risk or severity of adverse effects can be increased when Resveratrol is combined with Hydrocortisone.
Rifabutin
The serum concentration of Hydrocortisone can be decreased when it is combined with Rifabutin.
Rifampin
The serum concentration of Hydrocortisone can be decreased when it is combined with Rifampicin.
Rifapentine
The serum concentration of Hydrocortisone can be decreased when it is combined with Rifapentine.
Rifaximin
The serum concentration of Rifaximin can be increased when it is combined with Hydrocortisone.
Rilpivirine
The serum concentration of Rilpivirine can be decreased when it is combined with Hydrocortisone.
Rivastigmine
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Rivastigmine.
Rofecoxib
The risk or severity of adverse effects can be increased when Rofecoxib is combined with Hydrocortisone.
Roflumilast
Roflumilast may increase the immunosuppressive activities of Hydrocortisone.
Rosiglitazone
The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Hydrocortisone.
Rosoxacin
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Rosoxacin.
Rosuvastatin
The serum concentration of Rosuvastatin can be increased when it is combined with Hydrocortisone.
ROTAVIRUS VACCINE, LIVE
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Rotavirus Vaccine.
Rubella Virus Vaccine Live (wistar Ra 27-3 Strain)
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Rubella virus vaccine.
Rucaparib
The metabolism of Hydrocortisone can be decreased when combined with Rucaparib.
Salicylamide
The risk or severity of adverse effects can be increased when Salicylamide is combined with Hydrocortisone.
Salicylic Acid
The risk or severity of adverse effects can be increased when Salicylic acid is combined with Hydrocortisone.
Salmonella enterica subsp. enterica serovar typhi
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Salmonella typhi ty21a live antigen.
Salsalate
The risk or severity of adverse effects can be increased when Salsalate is combined with Hydrocortisone.
Saquinavir
The metabolism of Hydrocortisone can be decreased when combined with Saquinavir.
Saquinavir Mesylate
The metabolism of Hydrocortisone can be decreased when combined with Saquinavir.
Sarilumab
The therapeutic efficacy of Hydrocortisone can be decreased when used in combination with Sarilumab.
Saxagliptin
The serum concentration of Saxagliptin can be decreased when it is combined with Hydrocortisone.
Saxagliptin Anhydrous
The serum concentration of Saxagliptin can be decreased when it is combined with Hydrocortisone.
Serratiopeptidase
The risk or severity of adverse effects can be increased when Serrapeptase is combined with Hydrocortisone.
Sildenafil
The metabolism of Hydrocortisone can be decreased when combined with Sildenafil.
Silodosin
The serum concentration of Silodosin can be increased when it is combined with Hydrocortisone.
Siltuximab
The serum concentration of Hydrocortisone can be decreased when it is combined with Siltuximab.
Simeprevir
The serum concentration of Hydrocortisone can be increased when it is combined with Simeprevir.
Simvastatin
The serum concentration of Simvastatin can be increased when it is combined with Hydrocortisone.
sipuleucel-T
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Hydrocortisone.
Sitagliptin
The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Hydrocortisone.
Sitagliptin Phosphate
The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Hydrocortisone.
Sodium Bicarbonate
The bioavailability of Hydrocortisone can be decreased when combined with Sodium bicarbonate.
Sparfloxacin
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Sparfloxacin.
ST. JOHN'S WORT EXTRACT
The serum concentration of Hydrocortisone can be decreased when it is combined with St. John's Wort.
Stanozolol
Hydrocortisone may increase the fluid retaining activities of Stanozolol.
Sulfasalazine
The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Hydrocortisone.
Sulfisoxazole
The metabolism of Hydrocortisone can be decreased when combined with Sulfisoxazole.
Sulindac
The risk or severity of adverse effects can be increased when Sulindac is combined with Hydrocortisone.
Suprofen
The risk or severity of adverse effects can be increased when Suprofen is combined with Hydrocortisone.
synthetic conjugated estrogens, A
The serum concentration of Hydrocortisone can be increased when it is combined with Synthetic Conjugated Estrogens, A.
synthetic conjugated estrogens, B
The serum concentration of Hydrocortisone can be increased when it is combined with Synthetic Conjugated Estrogens, B.
Tacrine
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Tacrine.
Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Hydrocortisone.
Telaprevir
The serum concentration of Telaprevir can be decreased when it is combined with Hydrocortisone.
Telithromycin
The metabolism of Hydrocortisone can be decreased when combined with Telithromycin.
Temafloxacin
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Temafloxacin.
Tenoxicam
The risk or severity of adverse effects can be increased when Tenoxicam is combined with Hydrocortisone.
Teriflunomide
The risk or severity of adverse effects can be increased when Teriflunomide is combined with Hydrocortisone.
Testosterone
Hydrocortisone may increase the fluid retaining activities of Testosterone.
Testosterone Cypionate
Hydrocortisone may increase the fluid retaining activities of Testosterone cypionate.
Testosterone Enanthate
Hydrocortisone may increase the fluid retaining activities of Testosterone enanthate.
Testosterone Propionate
Hydrocortisone may increase the fluid retaining activities of Testosterone propionate.
Testosterone Undecanoate
Hydrocortisone may increase the fluid retaining activities of Testosterone undecanoate.
Tetanus Toxoid Vaccine, Inactivated
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).
Tiaprofenic Acid
The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Hydrocortisone.
Tibolone
The serum concentration of Hydrocortisone can be increased when it is combined with Tibolone.
Ticlopidine
The metabolism of Hydrocortisone can be decreased when combined with Ticlopidine.
Tocilizumab
The serum concentration of Hydrocortisone can be decreased when it is combined with Tocilizumab.
Tofacitinib
Hydrocortisone may increase the immunosuppressive activities of Tofacitinib.
Tolazamide
The therapeutic efficacy of Tolazamide can be decreased when used in combination with Hydrocortisone.
Tolbutamide
The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Hydrocortisone.
Tolfenamic Acid
The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Hydrocortisone.
Tolmetin
The risk or severity of adverse effects can be increased when Tolmetin is combined with Hydrocortisone.
Tolvaptan
The serum concentration of Tolvaptan can be increased when it is combined with Hydrocortisone.
Topotecan
The serum concentration of Topotecan can be increased when it is combined with Hydrocortisone.
Torsemide
Hydrocortisone may increase the hypokalemic activities of Torasemide.
Tranilast
The risk or severity of adverse effects can be increased when Tranilast is combined with Hydrocortisone.
Trastuzumab
Trastuzumab may increase the neutropenic activities of Hydrocortisone.
Trichlormethiazide
Hydrocortisone may increase the hypokalemic activities of Trichlormethiazide.
Troglitazone
The therapeutic efficacy of Troglitazone can be decreased when used in combination with Hydrocortisone.
Trolamine Salicylate
The risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Hydrocortisone.
Tromethamine
The bioavailability of Hydrocortisone can be decreased when combined with Tromethamine.
Trovafloxacin
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Trovafloxacin.
Tubocurarine
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Tubocurarine.
Typhoid Vaccine Live Ty21a
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Salmonella typhi ty21a live antigen.
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Salmonella typhi ty2 vi polysaccharide antigen.
Valdecoxib
The risk or severity of adverse effects can be increased when Valdecoxib is combined with Hydrocortisone.
Varicella Virus Vaccine Live (Oka-Merck) strain
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Varicella Zoster Vaccine (Live/Attenuated).
Vemurafenib
The serum concentration of Hydrocortisone can be increased when it is combined with Vemurafenib.
Venlafaxine
The metabolism of Hydrocortisone can be decreased when combined with Venlafaxine.
Verapamil
The metabolism of Hydrocortisone can be decreased when combined with Verapamil.
Vildagliptin
The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Hydrocortisone.
Vincristine
The excretion of Vincristine can be decreased when combined with Hydrocortisone.
Voriconazole
The metabolism of Hydrocortisone can be decreased when combined with Voriconazole.
Warfarin
Hydrocortisone may increase the anticoagulant activities of Warfarin.
Yellow Fever Vaccine
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Yellow Fever Vaccine.
Yellow-Fever Virus Vaccine, 17D-204 strain
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Yellow Fever Vaccine.
Zileuton
The risk or severity of adverse effects can be increased when Zileuton is combined with Hydrocortisone.
Ziprasidone
The metabolism of Hydrocortisone can be decreased when combined with Ziprasidone.
Zomepirac
The risk or severity of adverse effects can be increased when Zomepirac is combined with Hydrocortisone.
